NO20092729L - Lipasevarianter for farmasoytisk anvendelse - Google Patents

Lipasevarianter for farmasoytisk anvendelse

Info

Publication number
NO20092729L
NO20092729L NO20092729A NO20092729A NO20092729L NO 20092729 L NO20092729 L NO 20092729L NO 20092729 A NO20092729 A NO 20092729A NO 20092729 A NO20092729 A NO 20092729A NO 20092729 L NO20092729 L NO 20092729L
Authority
NO
Norway
Prior art keywords
lipases
digestive
improved
pharmaceutical use
diabetes
Prior art date
Application number
NO20092729A
Other languages
English (en)
Inventor
Peter-Colin Gregory
Allan Svendsen
Michael Skjot
Debbie Yaver
Lars Lehmann Hylling Christensen
Signe Eskildsen Larsen
Nina Lundin
Michael Lamsa
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of NO20092729L publication Critical patent/NO20092729L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Sammendrag Den farmasøytiske anvendelsen av lipaser som er beslektet med lipasen fra Thermomyces lanuginosus (Humicola lanuginosa) som omfatter aminosyrene 1-269 ifølge SEQ ID NO:2, alternativt i kombinasjon med en protease og/eller en amylase. Eksempler på medisinske indikasjoner er: behandling av fordøyelsesforstyrrelser, pankreatisk eksokrin mangel (PEI), pankreaitt, cystisk fibrose, diabetes type I og/eller diabetes type II. Lipasene ifølge oppfinnelsen har for eksempel en forbedret fordøyelseseffektivitet in vitro, en forbedret aktivitet ved en pH i det nøytrale området, en forbedret stabilitet ved lav pH, og er stabile mot proteasedegradering og/eller er stabile i nærvær av pepsin eller gallesalter. Oppfinnelsen vedrører også fremgangsmåter for bestemmelse av fordøyelsesaktivitet in vitro av lipaser, så vel som visse nye varianter av lipasen fra T. lanuginosus.
NO20092729A 2006-12-21 2009-07-20 Lipasevarianter for farmasoytisk anvendelse NO20092729L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Publications (1)

Publication Number Publication Date
NO20092729L true NO20092729L (no) 2009-09-18

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092729A NO20092729L (no) 2006-12-21 2009-07-20 Lipasevarianter for farmasoytisk anvendelse

Country Status (16)

Country Link
US (3) US8273348B2 (no)
EP (6) EP2455462B1 (no)
JP (1) JP5406040B2 (no)
KR (1) KR20090101930A (no)
CN (2) CN105112386A (no)
AR (1) AR064494A1 (no)
AU (1) AU2007337150A1 (no)
BR (1) BRPI0721103A2 (no)
CA (3) CA3081308C (no)
IL (1) IL198893A0 (no)
MX (1) MX2009006597A (no)
NO (1) NO20092729L (no)
RU (1) RU2009128067A (no)
TW (1) TW200829698A (no)
WO (1) WO2008079685A2 (no)
ZA (1) ZA200903598B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO2007014896A1 (en) 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2455462B1 (en) 2006-12-21 2016-03-16 Novozymes A/S Lipase variants for pharmaceutical use
DK2254996T3 (da) 2008-02-29 2013-10-07 Dsm Ip Assets Bv Lipaser med høj specificitet for kortkædede fedtsyrer og anvendelser deraf
CN102112602A (zh) * 2008-02-29 2011-06-29 宝洁公司 包含脂肪酶的洗涤剂组合物
US9163203B2 (en) * 2008-02-29 2015-10-20 Novozymes A/S Lipolytic enzyme variant with improved stability and polynucleotides encoding same
DK2734633T3 (da) 2011-07-22 2019-06-11 Novozymes North America Inc Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
CN111187676A (zh) 2011-12-29 2020-05-22 诺维信公司 具有脂肪酶变体的洗涤剂组合物
EP2809779B1 (en) * 2012-02-03 2017-09-13 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2013149858A1 (en) 2012-04-02 2013-10-10 Novozymes A/S Lipase variants and polynucleotides encoding same
CN104736700B (zh) * 2012-10-12 2019-02-01 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
BR112015028666B8 (pt) * 2013-05-14 2022-08-09 Novozymes As Composição detergente, método para produzir a mesma, método para a limpeza de um objeto e usos da composição
EP3022299B1 (en) * 2013-07-19 2020-03-18 Danisco US Inc. Compositions and methods comprising a lipolytic enzyme variant
US10287562B2 (en) * 2014-11-20 2019-05-14 Novoszymes A/S Alicyclobacillus variants and polynucleotides encoding same
WO2016087401A1 (en) * 2014-12-05 2016-06-09 Novozymes A/S Lipase variants and polynucleotides encoding same
MX2017007105A (es) * 2014-12-09 2017-08-24 Novozymes As Variantes de lipasa y polinucleotidos que las codifican.
CN107864658A (zh) 2015-04-07 2018-03-30 诺维信公司 用于选择具有脂肪酶活性的酶的方法
WO2017005640A1 (en) * 2015-07-03 2017-01-12 Novozymes A/S Detergent compositions with improved stability in the presence of sulfites
CN110462037A (zh) * 2017-01-30 2019-11-15 学校法人日本医科大学 腺相关病毒(aav)衣壳蛋白的突变体
MX2020002964A (es) * 2017-09-27 2020-07-22 Novozymes As Variantes de lipasa y composiciones de microcapsula que comprenden las variantes de lipasa.
JP7114697B2 (ja) * 2017-09-27 2022-08-08 ザ プロクター アンド ギャンブル カンパニー リパーゼを含む洗剤組成物
US20210071155A1 (en) * 2018-02-08 2021-03-11 Novozymes A/S Lipase Variants and Compositions Thereof
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
BR112023008326A2 (pt) * 2020-10-29 2023-12-12 Novozymes As Variantes de lipase e composições compreendendo tais variantes de lipase
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
AU657278B2 (en) 1990-09-13 1995-03-09 Novo Nordisk A/S Lipase variants
DK46693D0 (no) * 1993-04-23 1993-04-23 Novo Nordisk As
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
CA2331936C (en) 1990-12-05 2007-07-31 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
DK0585285T3 (da) 1991-05-01 1999-05-10 Novo Nordisk As Stabiliserede enzymer
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
JPH09503130A (ja) 1993-10-04 1997-03-31 ノボ ノルディスク アクティーゼルスカブ 修飾酵素を含んで成る酵素調製品
DE69527835T2 (de) 1994-02-22 2003-04-10 Novozymes As Methode zur herstellung einer variante eines lipolytischen enzymes
WO1996016177A1 (en) 1994-11-24 1996-05-30 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
US5856451A (en) 1994-12-07 1999-01-05 Novo Nordisk A/S Method for reducing respiratory allergenicity
WO1996023062A1 (en) 1995-01-26 1996-08-01 Novo Nordisk A/S Animal feed additives comprising xylanase
JP4307549B2 (ja) 1995-07-14 2009-08-05 ノボザイムス アクティーゼルスカブ 脂肪分解活性を有する修飾された酵素
US6495357B1 (en) 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
JP4068142B2 (ja) 1995-08-11 2008-03-26 ノボザイムス アクティーゼルスカブ 新規の脂肪分解酵素
EP0954572A1 (en) 1997-01-10 1999-11-10 Novo Nordisk A/S Enzyme coupled with polymeric molecules for skin care
EP1017794A1 (en) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
AU751880B2 (en) 1997-06-25 2002-08-29 Novozymes A/S A modified polypeptide
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU6078899A (en) 1998-10-13 2000-05-01 Novozymes A/S A modified polypeptide with reduced immune response
ES2220114T3 (es) 1998-10-30 2004-12-01 Novozymes A/S Variantes de proteinas poco alergenicas.
ES2289824T3 (es) 1998-10-30 2008-02-01 Novozymes A/S Proteinas glicosiladas con alergenicidad reducida.
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
NZ511340A (en) 1998-11-27 2003-07-25 Novozymes As Lipolytic enzyme variants
RU2268065C2 (ru) 1999-03-17 2006-01-20 Зольвай Фармасьютиклз Гмбх Лекарственное средство, предназначенное для лечения диабета
CA2366843A1 (en) 1999-03-31 2000-10-12 Jesper Vind Lipase variant
WO2000060063A1 (en) 1999-03-31 2000-10-12 Novozymes A/S Lipase variant
MX261332B (es) 2000-02-08 2008-10-14 Hoffmann La Roche Uso de proteasas estables en acido para alimento de animales.
US20020192792A1 (en) 2000-04-28 2002-12-19 Palle Schneider Laccase mutants
DK1352057T3 (da) 2001-01-10 2009-07-20 Novozymes As Upolytisk enzymvariant
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
AU2002229513A1 (en) 2001-02-07 2002-08-19 Novozymes A/S Lipase variants
WO2003060112A1 (en) * 2002-01-16 2003-07-24 Novozymes A/S Lipolytic enzyme variants and method for their production
US20060234340A1 (en) 2003-02-06 2006-10-19 Novozymes A/S Human heavy chain antibody expression in flamentous fungi
DK2270140T3 (en) * 2003-05-09 2016-03-14 Novozymes As Lipolytic enzyme variants
WO2004111216A2 (en) 2003-06-19 2004-12-23 Novozymes A/S Phospholipase variants
EP1639107B1 (en) 2003-06-19 2013-08-14 Novozymes A/S Improved proteases and methods for producing them
WO2005070962A1 (en) 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US7718169B2 (en) 2004-10-14 2010-05-18 Cystic Fibrosis Foundations Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
EP1851311A2 (en) 2005-02-10 2007-11-07 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
EP1896057A2 (en) 2005-06-24 2008-03-12 Novozymes A/S Amylases for pharmaceutical use
BRPI0611936A2 (pt) 2005-06-24 2011-02-22 Solvay Pharm Gmbh protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de doença
RU2007149045A (ru) * 2005-06-24 2009-07-10 Новозимс А/С (Dk) Липазы для фармацевтического применения
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
EP1979456A2 (en) 2006-01-23 2008-10-15 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
EP2371949B1 (en) * 2006-01-23 2017-04-19 Novozymes A/S Lipase variants
EP2455462B1 (en) * 2006-12-21 2016-03-16 Novozymes A/S Lipase variants for pharmaceutical use

Also Published As

Publication number Publication date
EP2455461B1 (en) 2016-03-16
IL198893A0 (en) 2010-02-17
EP2455459B1 (en) 2016-03-16
US20150209414A1 (en) 2015-07-30
US8273348B2 (en) 2012-09-25
WO2008079685A2 (en) 2008-07-03
CN105112386A (zh) 2015-12-02
US20120308543A1 (en) 2012-12-06
WO2008079685A3 (en) 2008-11-06
CN101743308B (zh) 2015-09-16
CA3081308A1 (en) 2008-07-03
MX2009006597A (es) 2009-07-02
JP5406040B2 (ja) 2014-02-05
US20100034797A1 (en) 2010-02-11
BRPI0721103A2 (pt) 2014-03-04
AR064494A1 (es) 2009-04-08
CA2670643C (en) 2017-04-25
EP2455462A3 (en) 2013-05-29
EP2455459A2 (en) 2012-05-23
EP2455462A2 (en) 2012-05-23
EP2455461A2 (en) 2012-05-23
TW200829698A (en) 2008-07-16
CA2961041C (en) 2020-07-14
US9029115B2 (en) 2015-05-12
EP2455460A3 (en) 2012-12-26
CN101743308A (zh) 2010-06-16
EP2455459A3 (en) 2013-04-24
CA2961041A1 (en) 2008-07-03
CA3081308C (en) 2024-02-20
EP2455461A3 (en) 2013-05-29
EP2261328A1 (en) 2010-12-15
ZA200903598B (en) 2010-04-28
KR20090101930A (ko) 2009-09-29
RU2009128067A (ru) 2011-01-27
CA2670643A1 (en) 2008-07-03
AU2007337150A1 (en) 2008-07-03
JP2010512795A (ja) 2010-04-30
EP2455462B1 (en) 2016-03-16
EP2261328B1 (en) 2013-11-20
EP2455460A2 (en) 2012-05-23
EP2099907A2 (en) 2009-09-16
US9539311B2 (en) 2017-01-10

Similar Documents

Publication Publication Date Title
NO20092729L (no) Lipasevarianter for farmasoytisk anvendelse
NO20080437L (no) Lipaser til farmasoytisk anvendelse
McClellan et al. Cellular functions and molecular mechanisms of non-lysine ubiquitination
Draganov Lactonases with oragnophosphatase activity: structural and evolutionary perspectives
Cornaciu et al. The minimal domain of adipose triglyceride lipase (ATGL) ranges until leucine 254 and can be activated and inhibited by CGI-58 and G0S2, respectively
Candas et al. MnSOD in oxidative stress response-potential regulation via mitochondrial protein influx
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
NO20080439L (no) Amylaser til farmasoytisk anvendelse
Chandrasekaran et al. In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity
NL300874I2 (nl) Elosulfase alfa
JP2010512795A5 (no)
NO20080438L (no) Proteaser til farmasoytisk anvendelse
RU2011102781A (ru) ПРИМЕНЕНИЕ Hsp70 В КАЧЕСТВЕ РЕГУЛЯТОРА ФЕРМЕНТАТИВНОЙ АКТИВНОСТИ
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
EP4241854A3 (en) Lysosomal storage disease enzyme
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
US11584920B2 (en) Use of enzymes with a wide pH activity range as medicaments for promoting digestion
Mandrich et al. Hyperthermophilic phosphotriesterases/lactonases for the environment and human health
Park et al. Catalytic properties of the PepQ prolidase from Escherichia coli
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721B (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721A (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
WO2008040739A3 (en) Lipolytic enzyme variants
Roy et al. Expression of recombinant human cathepsin K is enhanced by codon optimization
Lin et al. Benzene-di-N-octylcarbamates as conformationally constrained phospholipase A2 inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application